Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: a real-world observation study

por Ma, Ke, Guo, Qianqian, Li, Xingya
Publicado 2023

Amorphous Nanoparticulate Formulation of Sirolimus and Its Tablets

por Shen, Yudong, Li, Xingya, Le, Yuan
Publicado 2018

Cholesterol Metabolism as a Potential Therapeutic Target and a Prognostic Biomarker for Cancer Immunotherapy

por Zhang, Huixian, Zhao, Wencheng, Li, Xingya, He, Yayi
Publicado 2021

Advanced HCC with amplified mesenchymal epithelial transition factor receptor responds well to savolitinib: a case report

por Yan, Ningning, Zhang, Ziheng, Guo, Sanxing, Shen, Shujing, Li, Xingya
Publicado 2023

Corrigendum: Advanced HCC with amplified mesenchymal epithelial transition factor receptor responds well to savolitinib: a case report

por Yan, Ningning, Zhang, Ziheng, Guo, Sanxing, Shen, Shujing, Li, Xingya
Publicado 2023

Exosomal miR-126 blocks the development of non-small cell lung cancer through the inhibition of ITGA6

por Li, Mingjun, Wang, Qianqian, Zhang, Xiaofei, Yan, Ningning, Li, Xingya
Publicado 2020

Correction to: Exosomal miR-126 blocks the development of non-small cell lung cancer through the inhibition of ITGA6

por Li, Mingjun, Wang, Qianqian, Zhang, Xiaofei, Yan, Ningning, Li, Xingya
Publicado 2021

Successful treatment of lung adenocarcinoma complicated with a rare compound EGFR mutation L833V/H835L using aumolertinib: a case report and literature review

por Li, Linlin, Huang, Siyuan, Qin, Liying, Yan, Ningning, Shen, Shujing, Li, Xingya
Publicado 2023

Activity of ceritinib in crizotinib-resistant ROS1-rearranged non-small-cell lung cancer patients

por Zhang, Huixian, Li, Xingya, Zhang, Ziheng, Huang, Siyuan, Guo, Qianqian, Yan, Ningning
Publicado 2023

LINC01089 functions as a ceRNA for miR-152-3p to inhibit non‐small lung cancer progression through regulating PTEN

por Zhang, Huixian, Zhang, Hao, Li, Xingya, Huang, Siyuan, Guo, Qianqian, Geng, Di
Publicado 2021

Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M

por Wang, Yurong, Zheng, Ruipan, Hu, Peizhu, Zhang, Ziheng, Shen, Shujing, Li, Xingya
Publicado 2021

A Retrospective Study of Intrathecal Pemetrexed Combined With Systemic Therapy for Leptomeningeal Metastasis of Lung Cancer

por Geng, Di, Guo, Qianqian, Huang, Siyuan, Zhang, Huixian, Guo, Sanxing, Li, Xingya
Publicado 2022

BRAF-Mutated Non-Small Cell Lung Cancer: Current Treatment Status and Future Perspective

por Yan, Ningning, Guo, Sanxing, Zhang, Huixian, Zhang, Ziheng, Shen, Shujing, Li, Xingya
Publicado 2022

Alectinib versus crizotinib in ALK‐positive advanced non‐small cell lung cancer and comparison of next‐generation TKIs after crizotinib failure: Real‐world evidence

por Wang, Yurong, Shen, Shujing, Hu, Peizhu, Geng, Di, Zheng, Ruipan, Li, Xingya
Publicado 2022

Retraction Note: LINC01089 functions as a ceRNA for miR-152-3p to inhibit non‐small lung cancer progression through regulating PTEN

por Zhang, Huixian, Zhang, Hao, Li, Xingya, Huang, Siyuan, Guo, Qianqian, Geng, Di
Publicado 2022

The taxane-based chemotherapy triplet is superior to the doublet in one to nine node-positive but not node-negative triple-negative breast cancer: results from a retrospective anal...

por Guo, Sanxing, Shi, Yonggang, Lu, Shuo, He, Yujie, Jin, Guangyi, Zhang, Suzhi, Li, Xingya
Publicado 2020

MKL1-induced lncRNA SNHG18 drives the growth and metastasis of non-small cell lung cancer via the miR-211-5p/BRD4 axis

por Fan, Huijie, Yuan, Jing, Li, Yaqing, Jia, Yongxu, Li, Jing, Wang, Xiaofeng, Li, Xingya
Publicado 2021

Phase 1 Study of the Selective c-MET Inhibitor, HS-10241, in Patients With Advanced Solid Tumors

por Dong, Xiaorong, Li, Xingya, Chen, Jianhua, Ma, Shenglin, Mu, Deguang, Hu, Jie, Lu, Shun
Publicado 2022

Corrigendum: Case Report: Durable response to immuno-chemotherapy in a case of ROS1 fusion-positive advanced lung adenocarcinoma: A case report

por Yan, Ningning, Huang, Siyuan, Li, Linlin, Guo, Qianqian, Geng, Di, Zhang, Huixian, Guo, Sanxing, Li, Xingya
Publicado 2023

Case Report: Durable response to immuno-chemotherapy in a case of ROS1 fusion-positive advanced lung adenocarcinoma: A case report

por Yan, Ningning, Huang, Siyuan, Li, Linlin, Guo, Qianqian, Geng, Di, Zhang, Huixian, Guo, Sanxing, Li, Xingya
Publicado 2022